TY - JOUR
T1 - Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?
AU - Pezzilli, Raffaele
AU - Gabbrielli, Armando
AU - Morselli Labate, Antonio Maria
AU - D'Alessio, Pasquale
AU - Barakat, Bahjat
AU - Costamagna, Guido
AU - Dibenedetti, Francesco
AU - Massa, Margherita
AU - Merlini, Giovanni
AU - Melzi D'Eril, Gianvico
PY - 2003/5
Y1 - 2003/5
N2 - Background/Aims: To explore the possibility that the preventive effect of gabexate mesilate on endoscopic retrograde cholangiopancreatography-related acute pancreatitis may be mediated by its modulation of acute phase proteins. Methodology: Thirty consecutive patients who underwent endoscopic retrograde cholangiopancreatography were randomly assigned to receive 1g of gabexate mesilate (13 patients) or a placebo (17 patients) by continuous i.v. infusion starting 30 minutes before the endoscopy session and continuing for 12 hours afterward. In all patients, C-reactive protein, serum amyloid A and interleukin 6 serum concentrations were determined before endoscopy and 4, 8, 12 and 24 hours afterward. Results: Interleukin 6 basal serum concentrations were not statistically different between patients who had been treated with gabexate mesilate and those who had received the placebo (P=0.279), whereas C-reactive protein (P=0.033) and serum amyloid A (P=0.022) basal values were significantly lower in the gabexate mesilate group than in the placebo group. Compared to basal values, serum interleukin 6 concentrations significantly increased at 4 (P=0.048) and at 8 (P=0.025) hours; the increase of serum interleukin 6 concentrations was not significant at 12 (P=0.092), but became significant at 24 (P=0.025) hours. C-reactive protein and serum amyloid A serum concentrations increased significantly only at 12 (P=0.001, P=0.012, respectively) and 24 (P
AB - Background/Aims: To explore the possibility that the preventive effect of gabexate mesilate on endoscopic retrograde cholangiopancreatography-related acute pancreatitis may be mediated by its modulation of acute phase proteins. Methodology: Thirty consecutive patients who underwent endoscopic retrograde cholangiopancreatography were randomly assigned to receive 1g of gabexate mesilate (13 patients) or a placebo (17 patients) by continuous i.v. infusion starting 30 minutes before the endoscopy session and continuing for 12 hours afterward. In all patients, C-reactive protein, serum amyloid A and interleukin 6 serum concentrations were determined before endoscopy and 4, 8, 12 and 24 hours afterward. Results: Interleukin 6 basal serum concentrations were not statistically different between patients who had been treated with gabexate mesilate and those who had received the placebo (P=0.279), whereas C-reactive protein (P=0.033) and serum amyloid A (P=0.022) basal values were significantly lower in the gabexate mesilate group than in the placebo group. Compared to basal values, serum interleukin 6 concentrations significantly increased at 4 (P=0.048) and at 8 (P=0.025) hours; the increase of serum interleukin 6 concentrations was not significant at 12 (P=0.092), but became significant at 24 (P=0.025) hours. C-reactive protein and serum amyloid A serum concentrations increased significantly only at 12 (P=0.001, P=0.012, respectively) and 24 (P
KW - Acute Phase Proteins
KW - Clinical Study
KW - ERCP
KW - Gabexate
KW - Pancreatitis
UR - http://www.scopus.com/inward/record.url?scp=0038238640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038238640&partnerID=8YFLogxK
M3 - Article
C2 - 12828103
AN - SCOPUS:0038238640
VL - 50
SP - 851
EP - 855
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 51
ER -